MUHAMMAD AKRAM KHAN, M.D., M.B.A., F.A.C.C., F.S.C.A.I.
4201 MEDICAL CENTER DRIVE, SUITE 380, MCKINNEY, TX 75069
Office: 972-529-6939
Fax: 972-529-6935
EDUCATION:
POSTGRADUATE TRAINING:
2011-2013
Physician Executive MBA
UT Southwestern Medical Center at UTD
Richardson, Texas
1996-97
Fellowship in Interventional Cardiology
Baylor University Medical Center
Dallas, Texas
1993-96
Fellowship in Cardiology
Baylor University Medical Center
Dallas, Texas
1991-93
Residency in Medicine
Wayne State University Medical Center
Detroit, Michigan
1990-93
Internship in Medicine
Wayne State University Medical Center
Detroit, Michigan
MEDICAL SCHOOL:
1982-89
Dow Medical College
Karachi, Pakistan – M.B.B.S.
COLLEGE:
1979-81
St. Patrick’s College
Karachi, Pakistan
HOSPITAL/ACADEMIC
APPOINTMENTS:
July 2013 Laureate, American College of Cardiology
2003-Present Physician / President
Cardiac Center of Texas, P.A.
McKinney, Texas
February 2013 - Present Co-Director
Department of Palliative Care at Medical Center of Plano
2007-Present Co-Director
Department of Peripheral Vascular Disease at Medical
Center of Plano
November 2010 – Present Medical Director
Preventive Medicine Department at Medical Center of Plano
Page 1 of 7
M. Akram Khan, MD, FACC, FSCAI
July 2009 Founding Member IRB Committee at The
Medical Center of Plano
2000-Present Principal Investigator
NORTH DALLAS RESEARCH ASSOCIATES
McKinney, Texas
2005, 2002, 2001, 2000, 1999 Chief of Cardiology Dept.
Medical Center of McKinney/North Central Medical Center
McKinney, Texas
2002-2004
Department Chair of Medicine
Presbyterian Hospital of Allen
Allen, Texas
2004 Peer Review Committee Member
North Central Medical Center Hospital
McKinney, Texas
2004 Vice-Chief of Cardiology
North Central Medical Center Hospital
McKinney, Texas
2002 Pharmacy & Therapeutics Committee Member
Medical Center of Plano
Plano, Texas
2002 Member
Cardiovascular Performance & Improvement Team
North Central Medical Center Hospital
McKinney, Texas
2002-2003
Physician / Vice President
Cardiovascular Physicians of North Texas, P.A.
McKinney, Texas
1997-2002
Director of McKinney Clinic
CPR / HeartPlace
McKinney, Texas
2003
Fellow, Society for Cardiac Angiography &
Interventions
1999-2003
Director of Cardiac Catheterization Lab
North Central Medical Center
McKinney, Texas
1992-93
Chief Medical Resident
Wayne State University Medical Center
Detroit, Michigan
Page 2 of 7
M. Akram Khan, MD, FACC, FSCAI
1999
Fellow, American College of Cardiology
BOARD CERTIFICATION(S):
2013
Diplomat in Phlebology
American Board of Venous and Lymphatic Medicine
2012
Diplomat in Hospice and Palliative Medicine
American Board of Internal Medicine
2000
Diplomat in Interventional Cardiology
American Board of Internal Medicine – Recertification 2012
1998
Diplomat in Cardiovascular Disease
American Board of Internal Medicine – Recertification 2009
1993 - 2008
Diplomat in Internal Medicine
American Board of Internal Medicine
OTHER CERTIFICATION:
2011
Certified Clinical Research Professional
Society of Clinical Research Associates
STATE LICENSURE(S):
Licensed Physician, State of Texas
MEMBERSHIPS:
American College of Phlebology
American Academy of Hospice and Palliative Medicine
Society of Clinical Research Associates
Society of Cardiovascular Computed Tomography – Level 2
Accredited
Society for Cardiovascular Angiography & Interventions
Wyeth Pharmaceuticals Visiting Speakers Bureau
Forest Pharmaceuticals Visiting Speakers Bureau
Medical Group Management Association
Academy of Physicians in Clinical Research
Association of Clinical Research Professionals
International Society of Endovascular Specialists
Outpatient Endovascular and Interventional Society
American College of Cardiology
American Heart Association
American College of Physicians
Texas Medical Association
Collin-Fannin County Medical Society
Society for Women’s Health Research
Page 3 of 7
M. Akram Khan, MD, FACC, FSCAI
HONORS:
First in Undergraduate School – Gold Medallist
Among top 1% on all professional exams
Federal Government Merit Scholarship
Pakistan Govt. Scholarship for Studying Medicine Abroad
PUBLICATIONS:
1.
Khan, MA, Granda J. An atypical case of pituitary apoplexy. Abstract presented at 1991
Annual Session. ACP, Michigan Chapter
2.
Spears, JR, Yellayi SS, Khan MA, Promm B. Effects of thermal exposure on binding of
heparin in vivo to the arterial wall and to clot and on the chronic angiographic luminal
responses to local application of a heparin film during angioplasty in an in view rabbit
model. Lasers in Surgery Medicine. 1994;14:329-346.
3.
Khan MA, Gerber TL, Anwar A. Percutaneous interventions for significant narrowings in
saphenous vein aortocoronary conduits. Baylor University Medical Center Proceedings.
1995;5:19-25.
4.
Khan MA, Gerber TX, Schreibfeder MM, Bret JR, Donsky MS, Leonard BM, Solis RM,
Anwar A. The Elderly and Angioplasty: Does Gender Affect Outcome? American Journal
Ger Cardiology. 1996;5(2):55.
ONGOING RESEARCH PROJECTS:
DAPT: A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the
Effectiveness and Safety of 12 Versus 30 Months of Dual Anti-platelet Therapy in Subjects
Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare
Metal Stent Placement for the Treatment of Coronary Artery Lesions.
CELESTIAL: Post Approval Registry: Corox OTW, Endocardial, Left Ventricular Steroid
Lead, Bipolar Post Approval Registry.
GALAXY Registry: Long-term Evaluation of the Linox Family ICD Leads Registry.
PROMISE: PROspective Multicenter Imaging Study for Evaluation of Chest Pain
1160.128: A prospective, open label study evaluating the efficacy of two management
strategies (pantoprazole 40 mg q.a.m. and taking Pradaxa with food (within 30 minutes
after a meal) on gastrointestinal symptoms (GIS) in patients newly on treatment with
Pradaxa 150mg b.i.d for the prevention of stroke and systemic embolism in patients with
non-valvular atrial fibrillation)
LIGHT STUDY: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight
Page 4 of 7
M. Akram Khan, MD, FACC, FSCAI
and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone
SR/Bupropion SR
CANTOS TRIAL: A randomized, double-blind, placebo-controlled, event driven trial of
quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events
among stable post-myocardial infarction patients with elevated hsCRP.
EUCLID: A randomized, double-blind, parallel group, multicentre phase IIIb study to
compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death,
myocardial infarction and ischaemic stroke in patients with
established Peripheral Artery Disease
BIOFLEX-I: The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Selfexpanding Astron and Pulsar Stents.
BIOHELIX: The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy
Cobalt-Chromium, Bare-Metal Stent
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of
Warfarin Therapy for an Elective Invasive Procedure or Surgery
PRIOR RESEACH PROJECTS:
Sub-Investigator Micardis Community Access Trial (MICCAT)
Investigator Hyperlipidemia Study with Mayo Physician Alliance for Clinical Trials
Investigator Hypertension and Hyperlipidemia Study
Investigator Hypertension Study
Investigator Hyperlipidemia Study
A Randomized, Double-Blind, Placebo- Controlled, Multicenter, Parallel-Arm Study to
Assess the Long-Term Effects of XXX Versus Placebo Administered Orally to Patients with
Intermittent Claudication Secondary to Peripheral Arterial Disease, 2003.
Effect of XXX Vs Placebo on a Background of Standard Care Including Aspirin, in
Maintaining the Patency of Lower Limb Arteries After Angioplasty, 2003
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Forced Titration,
Comparison of XXX (XXX 80mg/XXX 25mg) Versus YYY (YYY 160mg/ YYY25mg) using
Seated Trough Cuff Blood Pressure in Patients with Stage 1 and Stage 2 Hypertension,
2003
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of XXX
in the Treatment of Patients with Type 2 Diabetes Mellitus, 2003
A Placebo-Controlled Trial of XXX Added to Standard Therapy in African American
Heart Failure, 2003
Page 5 of 7
M. Akram Khan, MD, FACC, FSCAI
A Dose Response of XXX ER/YYY on Peak Walking Time (PWT) in Patients with
Intermittent Claudication, 2003
An open-Label, Comparative Efficacy Evaluation of Lipids Levels when Treated with XXX
and YYY or Other Lipid-Modifying Therapies, 2004
A Double-Blind, Randomized, Comparator-Controlled Study in Subjects with Type 2
Diabetes Mellitus Comparing the Effects of XXX HCL Versus YYY on the Rate of
Progression of Coronary Atheroscelrotic Disease as Measured by Intravascular
Ultrasound, 2004.
The Effect of XXX ER/YYY on Peak Walking Time in Patients with Intermittent
Claudication, 2004
A phase 3 double blind randomized multisite trial of the efficacy, safety and tolerability of
the fixed combination XXX/XXX administered orally, once daily for 12 months compared
to XXX alone titrated based on NCEP ATP-III LDL-C goals in subjects with Fredrickson
Types IIA and IIB Dyslipidemias, 2005
User Versus Tech Study Using the CoaguChek XS Meter with CoaguChek XS System PT
Tests, 2005
A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of XXX400
mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in
Patients with Atrial Fibrillation/Atrial Flutter (AF/AFL), 2005
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of XXX 50 MG,
100 MG or Placebo When Co-Administered with XXX 10 MG or 20 MG in Subjects with
Primary Hypercholesterolemia, 2005
An 8-Week, Randomized, Double-Blind, Parallel Group, Multi-Center, Placebo and Active
Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of XXX (150 Mg and
300 Mg) Administered Alone and in Combination with XXX (160 Mg and 320 Mg) in
Patients with Hypertension, 2006
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 4 x 4 Factorial Design
to Evaluate XXX 20, 40 and 80 Mg Tablets in Combination with XXX 2.5, 5 and 10 Mg
Capsules After Eight Weeks of Treatment in Patients with Stage I or II hypertension, With
an ABPM Sub-Study, 2006
A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and
Efficacy of XXX and XXX Combination Therapy to XXX and XXX Monotherapy in
Subjects with Mixed Dyslipidemia, 2006
A Long Term, Open-Label, Safety Extension Study of the Combination of XXX and XXX
Therapy for Subjects with Mixed Dyslipidemia, 2006
Page 6 of 7
M. Akram Khan, MD, FACC, FSCAI
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of
XXX, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary
Artery Disease, 2006
Randomized Evaluation of Long Term Anticoagulant Therapy Comparing the
Efficacy and Safety of Two Blinded Doses of XXX with Open Label XXX for the
Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial
Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial, 2006
Sub-Investigator Micardis Community Access Trial (MICCAT)
Investigator Hyperlipidemia Study with Mayo Physician Alliance for Clinical Trials
Investigator Hypertension and Hyperlipidemia Study
Investigator Hypertension Study
Investigator Hyperlipidemia Study
A Randomized, Double-Blind, Placebo- Controlled, Multicenter, Parallel-Arm Study to Assess the
Long-Term Effects of XXX Versus Placebo Administered Orally to Patients with Intermittent
Claudication Secondary to Peripheral Arterial Disease, 2003.
Effect of XXX Vs Placebo on a Background of Standard Care Including Aspirin, in Maintaining
the Patency of Lower Limb Arteries After Angioplasty, 2003
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Forced Titration, Comparison
of XXX (XXX 80mg/XXX 25mg) Versus YYY (YYY 160mg/ YYY25mg) using Seated Trough Cuff
Blood Pressure in Patients with Stage 1 and Stage 2 Hypertension, 2003
A Multi-center, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of XXX in the
Treatment of Patients with Type 2 Diabetes Mellitus, 2003
A Placebo-Controlled Trial of XXX Added to Standard Therapy in African American Heart
Failure, 2003
A Dose Response of XXX ER/YYY on Peak Walking Time (PWT) in Patients with Intermittent
Claudication, 2003
REFERENCES:
Page 7 of 7
Available upon request.
M. Akram Khan, MD, FACC, FSCAI